Enamine logo

Enamine

Enamine was founded in 1991 with the advent of high throughput screening in early drug discovery. The driving force of the company’s development was the rapidly increasing demand for new chemical compounds. Over the past 20 years, Enamine has become a global provider of Screening Compounds, Building Blocks, and Fragments for supporting a wide range of research programs conducted by pharmaceutical and biotech companies, drug discovery centres, academic institutions and other research organizations worldwide. The company is committed to providing Life Science industries with a one-stop-shop solution for a wide spectrum of research needs. In order to deliver on this ambitious statement, the company is constantly expanding its team of highly skilled chemists, biologists, and engineers, which now is above 2000 people.
The Enamine headquarters occupy the space of 7 acres in Kyiv, Ukraine with multiple buildings for chemical and analytical labs, compound stock facilities, operations and business departments. The Enamine established chemistry sub-devisions in Germany and Latvia,  pharmacology and screening branch in Poland. The company has several stock facilities in the USA and Europe and it works through authorized representatives in Asian region.

Content by Enamine

Human corona viruses
| 2 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue